Global Non-small Cell Lung Cancer Therapeutics Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023

  • receipt Report ID : 147491
  • calendar_today Published On: Apr, 2019
  • file_copy Pages: 137
  • list Medical Devices

Non-small-cell lung carcinoma (NSCLC) is any type of epithelial lung cancer other than small cell lung carcinoma (SCLC). NSCLC accounts for about 85% of all lung cancers.

Scope of the Report:

This report focuses on the Non-small Cell Lung Cancer Therapeutics in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.

The worldwide market for Non-small Cell Lung Cancer Therapeutics is expected to grow at a CAGR of roughly 7.4% over the next five years, will reach 10200 million US$ in 2023, from 6660 million US$ in 2017, according to a new GIR (Global Info Research) study.

Market Segment by Manufacturers, this report covers

GlaxoSmithKline

Novartis

AstraZeneca

Roche

Bristol-Myers Squibb

Pfizer

Eli Lilly

Sanofi

Market Segment by Regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia and Italy)

Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

South America (Brazil, Argentina, Colombia etc.)

Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)

Market Segment by Type, covers

Alimta

Iressa

Avastin

Tarceva

Zykadia

Tagrisso

Xalkori

Cyramza

Opdivo

Alecensa

Market Segment by Applications, can be divided into

Hospital

Clinic

There are 15 Chapters to deeply display the global Non-small Cell Lung Cancer Therapeutics market.

Chapter 1, to describe Non-small Cell Lung Cancer Therapeutics Introduction, product scope, market overview, market opportunities, market risk, market driving force;

Chapter 2, to analyze the top manufacturers of Non-small Cell Lung Cancer Therapeutics, with sales, revenue, and price of Non-small Cell Lung Cancer Therapeutics, in 2016 and 2017;

Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;

Chapter 4, to show the global market by regions, with sales, revenue and market share of Non-small Cell Lung Cancer Therapeutics, for each region, from 2013 to 2018;

Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;

Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;

Chapter 12, Non-small Cell Lung Cancer Therapeutics market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;

Chapter 13, 14 and 15, to describe Non-small Cell Lung Cancer Therapeutics sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source

Frequently Asked Questions

The base year for the study has been considered 2019, historic year 2014 and 2018, the forecast period considered is from 2020 to 2027. The regions analyzed for the market include North America, Europe, South America, Asia Pacific, and Middle East and Africa. These regions are further analyzed at the country-level. The study also includes attractiveness analysis of type, application and regions which are benchmarked based on their market size, growth rate and attractiveness in terms of present and future opportunity for understanding the future growth of the market.

Market is segmented on the basis:

  • By Type
  • By Application
  • By Region
  • By Country
  • By Manufacturer

The report offers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a vital role in the enlargement of the market from 2019 to 2026.

The report provides company profile of the key players operating in the market and a comparative analysis based on their business overviews industry offering, segment market share, regional presence, business strategies, innovations, mergers & acquisitions, recent developments, joint venture, collaborations, partnerships, SWOT analysis, and key financial information.

Table of Contents

1 Market Overview

1.1 Non-small Cell Lung Cancer Therapeutics Introduction

1.2 Market Analysis by Type

1.2.1 Alimta

1.2.2 Iressa

1.2.3 Avastin

1.2.4 Tarceva

1.2.5 Zykadia

1.2.6 Tagrisso

1.2.7 Xalkori

1.2.8 Cyramza

1.2.9 Opdivo

1.2.10 Alecensa

1.3 Market Analysis by Applications

1.3.1 Hospital

1.3.2 Clinic

1.4 Market Analysis by Regions

1.4.1 North America (United States, Canada and Mexico)

1.4.1.1 United States Market States and Outlook (2013-2023)

1.4.1.2 Canada Market States and Outlook (2013-2023)

1.4.1.3 Mexico Market States and Outlook (2013-2023)

1.4.2 Europe (Germany, France, UK, Russia and Italy)

1.4.2.1 Germany Market States and Outlook (2013-2023)

1.4.2.2 France Market States and Outlook (2013-2023)

1.4.2.3 UK Market States and Outlook (2013-2023)

1.4.2.4 Russia Market States and Outlook (2013-2023)

1.4.2.5 Italy Market States and Outlook (2013-2023)

1.4.3 Asia-Pacific (China, Japan, Korea, India and Southeast Asia)

1.4.3.1 China Market States and Outlook (2013-2023)

1.4.3.2 Japan Market States and Outlook (2013-2023)

1.4.3.3 Korea Market States and Outlook (2013-2023)

1.4.3.4 India Market States and Outlook (2013-2023)

1.4.3.5 Southeast Asia Market States and Outlook (2013-2023)

1.4.4 South America, Middle East and Africa

1.4.4.1 Brazil Market States and Outlook (2013-2023)

1.4.4.2 Egypt Market States and Outlook (2013-2023)

1.4.4.3 Saudi Arabia Market States and Outlook (2013-2023)

1.4.4.4 South Africa Market States and Outlook (2013-2023)

1.4.4.5 Nigeria Market States and Outlook (2013-2023)

1.5 Market Dynamics

1.5.1 Market Opportunities

1.5.2 Market Risk

1.5.3 Market Driving Force

2 Manufacturers Profiles

2.1 GlaxoSmithKline

2.1.1 Business Overview

2.1.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.1.2.1 Product A

2.1.2.2 Product B

2.1.3 GlaxoSmithKline Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.2 Novartis

2.2.1 Business Overview

2.2.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.2.2.1 Product A

2.2.2.2 Product B

2.2.3 Novartis Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.3 AstraZeneca

2.3.1 Business Overview

2.3.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.3.2.1 Product A

2.3.2.2 Product B

2.3.3 AstraZeneca Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.4 Roche

2.4.1 Business Overview

2.4.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.4.2.1 Product A

2.4.2.2 Product B

2.4.3 Roche Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.5 Bristol-Myers Squibb

2.5.1 Business Overview

2.5.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.5.2.1 Product A

2.5.2.2 Product B

2.5.3 Bristol-Myers Squibb Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.6 Pfizer

2.6.1 Business Overview

2.6.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.6.2.1 Product A

2.6.2.2 Product B

2.6.3 Pfizer Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.7 Eli Lilly

2.7.1 Business Overview

2.7.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.7.2.1 Product A

2.7.2.2 Product B

2.7.3 Eli Lilly Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

2.8 Sanofi

2.8.1 Business Overview

2.8.2 Non-small Cell Lung Cancer Therapeutics Type and Applications

2.8.2.1 Product A

2.8.2.2 Product B

2.8.3 Sanofi Non-small Cell Lung Cancer Therapeutics Sales, Price, Revenue, Gross Margin and Market Share (2016-2017)

3 Global Non-small Cell Lung Cancer Therapeutics Sales, Revenue, Market Share and Competition by Manufacturer (2016-2017)

3.1 Global Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Manufacturer (2016-2017)

3.2 Global Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Manufacturer (2016-2017)

3.3 Market Concentration Rate

3.3.1 Top 3 Non-small Cell Lung Cancer Therapeutics Manufacturer Market Share in 2017

3.3.2 Top 6 Non-small Cell Lung Cancer Therapeutics Manufacturer Market Share in 2017

3.4 Market Competition Trend

4 Global Non-small Cell Lung Cancer Therapeutics Market Analysis by Regions

4.1 Global Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Market Share by Regions

4.1.1 Global Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Regions (2013-2018)

4.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Regions (2013-2018)

4.2 North America Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

4.3 Europe Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

4.4 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

4.5 South America Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

4.6 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

5 North America Non-small Cell Lung Cancer Therapeutics by Countries

5.1 North America Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Market Share by Countries

5.1.1 North America Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Countries (2013-2018)

5.1.2 North America Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)

5.2 United States Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

5.3 Canada Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

5.4 Mexico Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

6 Europe Non-small Cell Lung Cancer Therapeutics by Countries

6.1 Europe Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Market Share by Countries

6.1.1 Europe Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Countries (2013-2018)

6.1.2 Europe Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)

6.2 Germany Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

6.3 UK Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

6.4 France Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

6.5 Russia Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

6.6 Italy Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

7 Asia-Pacific Non-small Cell Lung Cancer Therapeutics by Countries

7.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Market Share by Countries

7.1.1 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Countries (2013-2018)

7.1.2 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)

7.2 China Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

7.3 Japan Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

7.4 Korea Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

7.5 India Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

7.6 Southeast Asia Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

8 South America Non-small Cell Lung Cancer Therapeutics by Countries

8.1 South America Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Market Share by Countries

8.1.1 South America Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Countries (2013-2018)

8.1.2 South America Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)

8.2 Brazil Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

8.3 Argentina Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

8.4 Colombia Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

9 Middle East and Africa Non-small Cell Lung Cancer Therapeutics by Countries

9.1 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Market Share by Countries

9.1.1 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Countries (2013-2018)

9.1.2 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Countries (2013-2018)

9.2 Saudi Arabia Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

9.3 UAE Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

9.4 Egypt Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

9.5 Nigeria Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

9.6 South Africa Non-small Cell Lung Cancer Therapeutics Sales and Growth Rate (2013-2018)

10 Global Non-small Cell Lung Cancer Therapeutics Market Segment by Type

10.1 Global Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Market Share by Type (2013-2018)

10.1.1 Global Non-small Cell Lung Cancer Therapeutics Sales and Market Share by Type (2013-2018)

10.1.2 Global Non-small Cell Lung Cancer Therapeutics Revenue and Market Share by Type (2013-2018)

10.2 Alimta Sales Growth and Price

10.2.1 Global Alimta Sales Growth (2013-2018)

10.2.2 Global Alimta Price (2013-2018)

10.3 Iressa Sales Growth and Price

10.3.1 Global Iressa Sales Growth (2013-2018)

10.3.2 Global Iressa Price (2013-2018)

10.4 Avastin Sales Growth and Price

10.4.1 Global Avastin Sales Growth (2013-2018)

10.4.2 Global Avastin Price (2013-2018)

10.5 Tarceva Sales Growth and Price

10.5.1 Global Tarceva Sales Growth (2013-2018)

10.5.2 Global Tarceva Price (2013-2018)

10.6 Zykadia Sales Growth and Price

10.6.1 Global Zykadia Sales Growth (2013-2018)

10.6.2 Global Zykadia Price (2013-2018)

10.7 Tagrisso Sales Growth and Price

10.7.1 Global Tagrisso Sales Growth (2013-2018)

10.7.2 Global Tagrisso Price (2013-2018)

10.8 Xalkori Sales Growth and Price

10.8.1 Global Xalkori Sales Growth (2013-2018)

10.8.2 Global Xalkori Price (2013-2018)

10.9 Cyramza Sales Growth and Price

10.9.1 Global Cyramza Sales Growth (2013-2018)

10.9.2 Global Cyramza Price (2013-2018)

10.10 Opdivo Sales Growth and Price

10.10.1 Global Opdivo Sales Growth (2013-2018)

10.10.2 Global Opdivo Price (2013-2018)

10.11 Alecensa Sales Growth and Price

10.11.1 Global Alecensa Sales Growth (2013-2018)

10.11.2 Global Alecensa Price (2013-2018)

11 Global Non-small Cell Lung Cancer Therapeutics Market Segment by Application

11.1 Global Non-small Cell Lung Cancer Therapeutics Sales Market Share by Application (2013-2018)

11.2 Hospital Sales Growth (2013-2018)

11.3 Clinic Sales Growth (2013-2018)

12 Non-small Cell Lung Cancer Therapeutics Market Forecast (2018-2023)

12.1 Global Non-small Cell Lung Cancer Therapeutics Sales, Revenue and Growth Rate (2018-2023)

12.2 Non-small Cell Lung Cancer Therapeutics Market Forecast by Regions (2018-2023)

12.2.1 North America Non-small Cell Lung Cancer Therapeutics Market Forecast (2018-2023)

12.2.2 Europe Non-small Cell Lung Cancer Therapeutics Market Forecast (2018-2023)

12.2.3 Asia-Pacific Non-small Cell Lung Cancer Therapeutics Market Forecast (2018-2023)

12.2.4 South America Non-small Cell Lung Cancer Therapeutics Market Forecast (2018-2023)

12.2.5 Middle East and Africa Non-small Cell Lung Cancer Therapeutics Market Forecast (2018-2023)

12.3 Non-small Cell Lung Cancer Therapeutics Market Forecast by Type (2018-2023)

12.3.1 Global Non-small Cell Lung Cancer Therapeutics Sales Forecast by Type (2018-2023)

12.3.2 Global Non-small Cell Lung Cancer Therapeutics Market Share Forecast by Type (2018-2023)

12.4 Non-small Cell Lung Cancer Therapeutics Market Forecast by Application (2018-2023)

12.4.1 Global Non-small Cell Lung Cancer Therapeutics Sales Forecast by Application (2018-2023)

12.4.2 Global Non-small Cell Lung Cancer Therapeutics Market Share Forecast by Application (2018-2023)

13 Sales Channel, Distributors, Traders and Dealers

13.1 Sales Channel

13.1.1 Direct Marketing

13.1.2 Indirect Marketing

13.1.3 Marketing Channel Future Trend

13.2 Distributors, Traders and Dealers

14 Research Findings and Conclusion

15 Appendix

15.1 Methodology

15.2 Data Source

List of Tables and Figures

Figure Non-small Cell Lung Cancer Therapeutics Picture

Table Product Specifications of Non-small Cell Lung Cancer Therapeutics

Figure Global Sales Market Share of Non-small

Please fill the form below, to recieve the report sample


+1

Choose License Type

Reach Us

Email us at

sales@mrinsights.biz

Or call us on

US +1-201-465-4211

IND +91-906-779-0957

Why Choose Us

ProactiveWe manage our resources 24/7 to identify issues and address them before they become problems

Quality & ReliabilityWe are committed to providing reliable and highly accurate data with an excellent quality control system

Global Outreach6 Major regions and 40+ countries level analysis accomplished

Competitive PricingOur pricing strategy is highly competitive in the market, without compensating on the quality and the timeline of project delivery